<DOC>
	<DOCNO>NCT02211625</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability , pharmacodynamics ( PD ) pharmacokinetics ( PK ) TRV734 give single dose ( Part A ) multiple ascend dos ( Part B ) healthy subject .</brief_summary>
	<brief_title>A Safety , Tolerability , PD PK Study Healthy Adults</brief_title>
	<detailed_description>This conduct two-parts enrol total approximately 72 healthy volunteer . - Part A ass safety , tolerability , PD PK 125mg dose TRV734 open-label , randomize , three-period crossover study subject fast , fed standard meal , feed high-fat meal . - Part B trial ass safety , tolerability , PD PK multiple ascending dos TRV734 double blind , double dummy , randomize , active- placebo-controlled , adaptive study . Oxycodone immediate release ( IR ) 10 mg use benchmark .</detailed_description>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Healthy determine responsible physician train qualified designee Males ( Part A ) males female ( Part B ) 18 &amp; 64 year age , inclusive . Females must nonchildbearing Capable give write informed consent Clinically significant condition , history faint syncope Medical psychiatric illness Major surgery within 4 week screen Known difficulty obtain intravenous access Any ophthalmologic condition could interfere pupillometry History sensitivity investigational product , know intolerance opioids history medication allergy Use prescription non prescription medication History drug abuse within 6 month screen Use illegal drug within 30 day screen throughout participation study History smoking use nicotine containing product within 3 month screen throughout participation study Donation blood plasma within 4 week prior dose Participation clinical trial receive medication within 30 day Weight &lt; 50 kg BMI outside range 18 32 kg/m2 Positive HIV antibody , hepatitis B virus surface antigen , hepatitis C virus If male , unwillingness abstain sexual intercourse pregnant lactate woman , engage sexual intercourse female partner childbearing potential , use condom spermicide , addition female partner use another form contraception , abstain sperm donation Part B Only : Active dermatological condition eczema nondominant hand . Peripheral vascular disease If female , child bear potential , pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Pharmacodynamics ( PD )</keyword>
	<keyword>Pharmacokinetics ( PK )</keyword>
</DOC>